AgeX Therapeutics (AGE) is an interesting company in the up-and-coming longevity space. This article will take a look at the science behind their current development programs as well as the leading figures and stakeholders in the company. AgeX is certainly a very risky bet, both because of the low probability of any preclinical asset eventually gaining approval and because it is unclear whether the company has the financial resources to develop their current pipeline assets. Despite that, I do believe the potential reward of success could be tremendous for investors, and the continued